Some clinicians opt to administer anti-VEGF agents at the end of vitrectomy combined with endolaser photocoagulation for PDR to reduce postoperative vitreous hemorrhage (Ahn et al., 2011; Sun et al., 2023). The gene discussed is VEGFA; the disease is vitreous hemorrhage.